- Paradigm Biopharmaceuticals (PAR) enters into a corporate partnership with NFL Alumni Health
- The partnership will inform NFL Alumni members about osteoarthritis disease onset, current treatment options, and provide information about clinical trials in the US
- NFL Alumni members include former NFL players, coaches, executives, spouses, cheerleaders, and associate members
- Paradigm CEO Marco Polizzi says it is an honour to be able to continue to work with the NFL Alumni members
- Paradigm are down 0.48 per cent to trade at $1.05 per share at 1:46 pm AEST
Paradigm Biopharmaceuticals (PAR) has entered into a corporate partnership with NFL Alumni Health.
The partnership will inform the NFL Alumni members about osteoarthritis disease onset, current treatment options, and provide information about actively enrolling clinical trials throughout the US.
NFL Alumni Health offers informational resources, programs, services, and other benefits to NFL Alumni members, such as former NFL players, coaches, executives, spouses,
cheerleaders, and associate members.
Paradigm was first introduced to the NFL Alumni Health by expanded access program participants, who have become strong advocates of its product Zilosul for knee
Previously, Paradigm has treated 10 former NFL players suffering from knee osteoarthritis. At the 12-week point, participants experienced an average of 65 per cent reduction in pain.
“In males under the age of 60, arthritis is over three times more prevalent in retired NFL players than in the general U.S. population,” NFL Alumni Association Co-Director of Healthcare Initatives Kyle Richardson said.
“We are pleased to hear the positive experience several of our alumni members have had through working with Paradigm and we hope this partnership will inform a larger number of alumni on the disease of osteoarthritis and the available clinical trials that are currently enrolling participants.”
Paradigm CEO Marco Polizzi said it is an honour to be able to continue to work with the NFL Alumni members.
“Having followed the progress of the expanded access program participants and hearing first-hand the positive impact Zilosul has had on their lives,” he said.
On the market, Paradigm was down 0.48 per cent to trade at $1.05 per share at 1:46 pm AEST.